Carbapenemase production among less-common Enterobacterales genera: 10 US sites, 2018.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
11
05
2021
accepted:
30
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Historically, United States' carbapenem-resistant Enterobacterales (CRE) surveillance and mechanism testing focused on three genera: From January through May 2018, we conducted a 10 state evaluation to assess the contribution of less common genera (LCG) to carbapenemase-producing (CP) CRE. State public health laboratories (SPHLs) requested participating clinical laboratories submit all Enterobacterales from all specimen sources during the surveillance period that were resistant to any carbapenem (Morganellaceae required resistance to doripenem, ertapenem, or meropenem) or were CP based on phenotypic or genotypic testing at the clinical laboratory. SPHLs performed species identification, phenotypic carbapenemase production testing, and molecular testing for carbapenemases to identify CP-CRE. Isolates were categorized as CP if they demonstrated phenotypic carbapenemase production and ≥1 carbapenemase gene ( SPHLs tested 868 CRE isolates, 127 (14.6%) were from eight LCG. Overall, 195 (26.3%) EsKE isolates were CP-CRE, compared with 24 (18.9%) LCG isolates. LCG accounted for 24 (11.0%) of 219 CP-CRE identified. Participating sites would have missed approximately 1 in 10 CP-CRE if isolate submission had been limited to EsKE genera. Expanding mechanism testing to additional genera could improve detection and prevention efforts.
Sections du résumé
BACKGROUND
BACKGROUND
Historically, United States' carbapenem-resistant Enterobacterales (CRE) surveillance and mechanism testing focused on three genera:
OBJECTIVES
OBJECTIVE
From January through May 2018, we conducted a 10 state evaluation to assess the contribution of less common genera (LCG) to carbapenemase-producing (CP) CRE.
METHODS
METHODS
State public health laboratories (SPHLs) requested participating clinical laboratories submit all Enterobacterales from all specimen sources during the surveillance period that were resistant to any carbapenem (Morganellaceae required resistance to doripenem, ertapenem, or meropenem) or were CP based on phenotypic or genotypic testing at the clinical laboratory. SPHLs performed species identification, phenotypic carbapenemase production testing, and molecular testing for carbapenemases to identify CP-CRE. Isolates were categorized as CP if they demonstrated phenotypic carbapenemase production and ≥1 carbapenemase gene (
RESULTS
RESULTS
SPHLs tested 868 CRE isolates, 127 (14.6%) were from eight LCG. Overall, 195 (26.3%) EsKE isolates were CP-CRE, compared with 24 (18.9%) LCG isolates. LCG accounted for 24 (11.0%) of 219 CP-CRE identified.
CONCLUSIONS
CONCLUSIONS
Participating sites would have missed approximately 1 in 10 CP-CRE if isolate submission had been limited to EsKE genera. Expanding mechanism testing to additional genera could improve detection and prevention efforts.
Identifiants
pubmed: 34514407
doi: 10.1093/jacamr/dlab137
pii: dlab137
pmc: PMC8417453
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlab137Informations de copyright
Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2021. This work is written by a US Government employee and is in the public domain in the US.
Références
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36
pubmed: 28375512
J Antimicrob Chemother. 2010 Dec;65(12):2695-7
pubmed: 20851814
Clin Microbiol Infect. 2018 Sep;24(9):1019.e5-1019.e8
pubmed: 29496594
Infect Control Hosp Epidemiol. 2018 Sep;39(9):1115-1117
pubmed: 30039775
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents
pubmed: 17630334
Antimicrob Resist Infect Control. 2018 Apr 24;7:55
pubmed: 29719718
Clin Microbiol Infect. 2014 Sep;20(9):821-30
pubmed: 24930781
J Clin Microbiol. 2017 Aug;55(8):2321-2333
pubmed: 28381609
MMWR Morb Mortal Wkly Rep. 2018 Jun 15;67(23):668-669
pubmed: 29902165
Emerg Infect Dis. 2018 Apr;24(4):700-709
pubmed: 29553324
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559268
MMWR Morb Mortal Wkly Rep. 2018 Apr 06;67(13):396-401
pubmed: 29621209
J Glob Antimicrob Resist. 2020 Sep;22:398-407
pubmed: 32311502
J Antimicrob Chemother. 2007 Mar;59(3):574-6
pubmed: 17251347
Infect Control Hosp Epidemiol. 2017 Mar;38(3):320-326
pubmed: 27923418
J Intern Med. 2015 May;277(5):501-12
pubmed: 25556628
MMWR Morb Mortal Wkly Rep. 2018 Jan 05;66(51-52):1410
pubmed: 29300717
Int J Antimicrob Agents. 2017 May;49(5):657-658
pubmed: 28336311
JAMA. 2015 Oct 13;314(14):1479-87
pubmed: 26436831
Am J Infect Control. 2020 Mar;48(3):320-323
pubmed: 31331713
J Clin Microbiol. 2003 Nov;41(11):4961-5
pubmed: 14605124
Int J Syst Evol Microbiol. 2016 Dec;66(12):5575-5599
pubmed: 27620848
MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1414-1415
pubmed: 27977640
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6418-21
pubmed: 27503648
South Med J. 2011 Jan;104(1):40-5
pubmed: 21119555
Medicina (Kaunas). 2019 Jun 18;55(6):
pubmed: 31216725
Antimicrob Agents Chemother. 2017 Apr 24;61(5):
pubmed: 28223374
J Am Geriatr Soc. 2002 Jul;50(7 Suppl):S230-5
pubmed: 12121518
Am J Infect Control. 2017 May 1;45(5):512-518
pubmed: 28456321
MMWR Morb Mortal Wkly Rep. 2018 Jun 29;67(25):727-728
pubmed: 29953432
Clin Microbiol Rev. 2000 Oct;13(4):534-46
pubmed: 11023955
Microb Drug Resist. 2006 Winter;12(4):223-30
pubmed: 17227206
Emerg Infect Dis. 2013 Jun;19(6):870-8
pubmed: 23731823
J Clin Microbiol. 2015 Jul;53(7):2324-8
pubmed: 25878341
Infect Control Hosp Epidemiol. 2020 Jan;41(1):1-18
pubmed: 31767041